Pharmacogenomics: New Technologies in the Development of Personalized Therapies

Table of Contents

• INTRODUCTION
  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS TO THE STUDY AND FOR WHOM
  • SCOPE AND FORMAT
  • METHODOLOGY
  • INFORMATION SOURCES
  • AUTHORS CREDENTIALS
  • RELATED BCC REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER
• SUMMARY
  • Summary Table: WORLDWIDE PHARMACOGENOMICS MARKET BY TECHNOLOGY SEGMENTS, THROUGH 2009 ($ MILLIONS)
  • Summary Figure: WORLDWIDE PHARMACOGENOMICS MARKET BY TECHNOLOGY SEGMENTS, 2001-2009 ($ MILLIONS)
• OVERVIEW
  • OVERVIEW
  • STREAMLINING CLINICAL TRIALS
    • TIME FRAME FOR DRUG APPROVAL
  • Table 1 DRUG DEVELOPMENT AND FDA APPROVAL PROCESS
    • HIGH COSTS STIFFLE INNOVATION
  • Table 2 NME APPROVALS GRANTED BY FDA (UNITED STATES), 1995-2004
  • Table 3 TOTAL SPENDING ON R&D BY PHRMA COMPANIES, 1999-2003 ($ BILLIONS)
  • Table 4 R&D SPENDING ON CLINICAL DEVELOPMENT BY PHRMA COMPANIES, BY DRUG DEVELOPMENT PHASE, 2002 ($ BILLIONS)
  • Figure 1 R&D SPENDING ON CLINICAL DEVELOPMENT BY PHRMA COMPANIES, BY DRUG DEVELOPMENT PHASE, 2002 ($ BILLIONS)
    • ATTRACTING TRIAL PARTICIPANTS
    • PHARMACOGENOMICS AS A SOLUTION
    • CAVEATS
    • IMPROVING DRUG EFFICACY
  • Table 5 DRUG INEFFICACY, BY THERAPY TYPE (PERCENTAGE OF PATIENTS FAILING TO RESPOND TO THERAPY)
    • REDUCING ADVERSE DRUG REACTIONS
      • FACTORS CONTRIBUTING TO ADVERSE DRUG REACTIONS
      • COSTS OFADVERSE DRUG REACTIONS
  • Table 6 ADVERSE DRUG REACTIONS IN THE UNITED STATES
    • MARKET DRIVERS
    • ROLE OF PHARMACOGENOMICS IN ADR PREVENTION
    • POST-MARKET DRUG FAILURE
      • PROMINENT DRUG WITHDRAWALS
  • Table 7 PROMINENT DRUGS WITHDRAWALS
    • Vioxx
    • Rezulin
    • Pondimin and Redux
    • Seldane
    • Posicor
    • Baycol (Cerivastatin)
    • ROLE OF PHARMACOGENOMICS IN REDUCING DRUG WITHDRAWALS
    • THE SNP CONSORTIUM
  • Table 8 SNP CONSORTIUM MEMBERS
    • THE INTERNATIONAL HAPMAP PROJECT
      • PARTICIPANTS IN THE HAPMAP PROJECT
  • Table 9 HAPMAP PARTICIPANTS AND FUNDING SOURCES
  • Table 10 STRUCTURE OF THE INTERNATIONAL HAPMAP PROJECT
  • Table 10 (CONTINUED)
    • HAPMAP POPULATIONS AND ETHICIAL CONCERNS
    • DATA ACCESSIBILITY AND PATENTABILITY
    • FOOD AND DRUG ADMINISTRATION: NEW GUIDELINES
      • FOOD AND DRUG ADMINISTRATION: NEW GUIDELINES (CONTINUED)
• SNP IDENTIFICATION MARKET
  • SNP IDENTIFICATION MARKET
  • Table 11 GLOBAL MARKET FOR SNP IDENTIFICATION TOOLS, THROUGH 2009 ($ MILLIONS)
  • Figure 2 GLOBAL MARKET FOR SNP IDENTIFICATION TOOLS, 2001-2009 ($ MILLIONS)
    • OVERVIEW OF SNP IDENTIFICATION
    • STRATEGIES FOR SNP IDENTIFICATION
      • CANDIDATE GENE SELECTION
      • WHOLE GENOME LINKAGE DISEQUILIBRIUM MAPPING
  • Table 12 EMERGING TECHNOLOGIES IN WHOLE GENOME MAPPING
    • COMBINATION STRATEGIES
    • SNP DATABASES
  • Table 13 MAJOR PRIVATE SNP DATABASES
    • COMPUTATIONAL TOOLS FOR SNP IDENTIFICATION
      • SNPBROWSER, APPLIED BIOSYSTEMS
      • CHROMOSOMEBROWSER?, ORCHID BIOSCIENCES
      • REALSNP, SEQUENOM
      • SNP KNOWLEDGE RESOURCE, ILLUMINA
      • CELERA DISCOVERY SYSTEM?, CELERA
• GENOTYPING MARKET
  • OVERALL MARKET FOR GENOTYPING TECHNOLOGIES
  • Table 14 GLOBAL MARKET FOR GENOTYPING TECHNOLOGIES BY PROTOCOL, THROUGH 2009 ($ MILLIONS)
  • Figure 3 GLOBAL MARKET FOR GENOTYPING TECHNOLOGIES BY PROTOCOL, 2001-2009 ($ MILLIONS)
    • GENOTYPING TECHNOLOGY OVERVIEW
    • ALLELIC DISCRIMINATION BY DNA POLYMERASES
  • Table 15 COMPARATIVE ADVANATAGES OF ALLELIC DISCRIMINATION METHODS
    • SINGLE-BASE EXTENSION
    • ALLELE-SPECIFIC EXTENSION
    • PYROSEQUENCING
    • STRUCTURE-SPECIFIC CLEAVAGE
    • TAQMAN ASSAY
  • Table 16 GLOBAL MARKET FOR ALLELE DISCRIMINATION TECHNOLOGIES BY TYPE, THROUGH 2009 ($ MILLIONS)
  • Figure 4 GLOBAL MARKET FOR ALLELE DISCRIMINATION TECHNOLOGIES BY TYPE, 2001-2009 ($ MILLIONS)
    • ALLELIC DISCRIMINATION BY HYBRIDIZATION
      • MICROARRAYS FOR GENOTYPING
  • Table 17 TOTAL GLOBAL MICROARRAY MARKET AND THAT FOR GENOTYPING APPLICATIONS, THROUGH 2009 ($ MILLIONS)
    • EMERGING TECHNOLOGY FOR ALLELIC DISCRIMINATION BY DNA LIGASES
    • DETECTION OF ALLELE-SPECIFIC PRODUCTS
  • Table 18 COMPARATIVE ADVANATAGES OF DETECTION METHODS
    • MASS SPECTROMETRY
  • Table 19 STRENGTHS AND WEAKENESSES OF MASS SPECTROMETRY FOR GENOTYPING
    • New Developments in Mass Spectrometry for DNA Analysis
  • Table 20 EMERGING TECHNOLOGIES IN DNA MASS SPECTROMETRY
    • FLUORESCENCE RESONANCE ENERGY TRANSFER
    • FLUORESCENCE POLARIZATION
    • LENGTH-BASED DETECTION SYSTEMS
  • Table 21 GLOBAL MARKET FOR GENOTYPING DETECTION TECHNOLOGIES BY TYPE, THROUGH 2009 ($ MILLIONS)
  • Figure 5 GLOBAL MARKET FOR GENOTYPING DETECTION TECHNOLOGIES BY TYPE, 2001-2009 ($ MILLIONS)
    • Length-based Detection Systems (continued)
    • COMPARISON OF COST AND THROUGHPUT
  • Table 22 COMPARISON OF GENOTYPING PLATFORMS COST AND THROUGHPUT
• PHARMACOGENOMICS DIAGNOSTICS MARKET
  • OVERALL MARKET FOR PHARAMCOGENOMICS DIAGNOSTICS
  • Table 23 GLOBAL MARKET FOR PHARMACOGENOMICS DIAGNOSTIC TOOLS BY TYPE, THROUGH 2009 ($ MILLIONS)
  • Figure 6 GLOBAL MARKET FOR PHARMACOGENOMICS DIAGNOSTIC TOOLS BY TYPE, 2001-2009 ($ MILLIONS)
    • MICROARRAYS
      • TECHNOLOGY OVERVIEW
      • PLANAR DNA MICROARRAYS
  • Table 24 MAJOR SUPPLIERS OF PLANAR DNA MICROARRAYS
  • Table 24 (CONTINUED)
    • ELECTRONIC MICROARRAYS
      • Nanochip (Nanogen, San Diego)
    • BEAD MICROARRAYS
    • EMERGING TECHNOLOGY: NANOPARTICLE ARRAYS
      • Verigene (Nanosphere, Chicago, IL)
      • Nanoplex Technologies (Mountain View, CA)
  • Table 25 MAJOR SUPPLIERS OF BEAD MICROARRAYS
    • MARKET FOR MICROARRAYS IN PHARMACOGENOMICS
    • MARKET FOR MICROARRAYS IN PHARMACOGENOMICS
  • Table 26 GLOBAL MARKET FOR MICROARRAYS IN PHARMACOGENOMICS BY TYPE, THROUGH 2009 (MILLIONS $)
  • Figure 7 GLOBAL MARKET FOR MICROARRAYS IN PHARMACOGENOMICS BY TYPE, 2001-2009 (MILLIONS $)
    • PCR-BASED ASSAYS
  • Table 27 MAJOR SUPPLIERS OF PCR-BASED ASSAYS
    • PCR-BASED TECHNOLOGIES
      • LightCycler (Roche Molecular Systems, Pleasanton, CA)
      • TaqMan DNA probes (Applied Biosystems, Foster City, CA)
      • Invader (Third Wave Technologies, Madison, WI)
      • Tag-It Mutation Assay (Tm Bioscience)
  • Table 28 GLOBAL MARKET FOR PCR ASSAYS IN PHARMACOGENOMICS RESEARCH BY TYPE, THROUGH 2009 ($ MILLIONS)
  • Figure 8 GLOBAL MARKET FOR PCR ASSAYS IN PHARMACOGENOMICS RESEARCH BY TYPE, 2001-2009 ($ MILLIONS)
    • IN SITU ANALYSIS
      • TECHNOLOGY
      • HER2 FISH TESTING
      • COMPARISON WITH IHC
  • Table 29 COMPARISON OF FISH AND IHC TESTING FOR HER2
  • Table 30 GLOBAL MARKET FOR IN SITU ASSAYS IN PHARMACOGENOMICS OF BREAST CANCER, THROUGH 2009 ($ MILLIONS)
• PHARMACOGENOMIC THERAPEUTICS BY DISEASE
  • CARDIOVASCULAR DISEASE
    • HEART FAILURE
      • Angiotensin I-Converting Enzyme (ACE)
      • BiDil
      • Projected Market for BiDil
  • Table 31 PROJECTED BIDILR MARKET, THROUGH 2009 ($ MILLIONS)
    • HYPERCHOLESTROLEMIA
  • Table 32 MAJOR PRODUCERS OF STATINS
    • Mechanism of Statins
    • Individual Variation Affects Statin Efficacy
    • STRENGTH Clinical Study of Statins
    • BREAST CANCER
      • BREAST CANCER AND HER2
        • Regulatory Guidelines
        • Emerging Herceptin Combination Market
  • Table 33 GLOBAL MARKET FOR HERCEPTIN, BY REGION, THROUGH 2009 ($ MILLIONS)
    • LEUKEMIA
      • CHRONIC MYELOID LEUKEMIA (CML)
        • Genetic Marker of CML
        • Gleevec
  • Table 34 GLOBAL MARKET FOR GLEEVEC/GLIVEC, BY REGION, THROUGH 2009 ($ MILLIONS)
    • ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    • ACUTE MYELOID LEUKEMIA (AML)
    • LUNG CANCER
      • NON-SMALL CELL LUNG CANCER
        • Clinical Studies on Iressa
        • Fast Track Approval in the US
        • Fast Track Approval in Japan
        • Post-Market Studies of Iressa
  • Table 35 GLOBAL SALES OF IRESSA PRIOR TO FDA ANNOUNCEMENT, 2002-2004 ($ MILLIONS)
    • ASTHMA
      • GENETIC VARIANTS AFFECTING ASTHMA THERAPY
  • Table 36 GENES OF INTEREST IN THE PHARMACOGENOMICS OF ASTHMA
    • MAJOR PLAYERS AND DEVELOPMENTS
  • Table 37 MAJOR PLAYERS IN PHARMACOGENOMICS OF ASTHMA TREATMENT
  • Table 38 GLOBAL MARKET FOR ASTHMA THERAPIES, BY TYPE, THROUGH 2009 ($ MILLIONS)
    • PHARMACOGENOMICS OF HIV/AIDS
      • VIRAL RESISTANCE
      • GENETIC RESISTANCE TESTING
  • Table 39 MAJOR SUPPLIERS OF HIV GENOTYPIC RESISTANCE TESTS
  • Table 40 GLOBAL MARKET FOR HIV RESISTANCE TESTING BY REGION, THROUGH 2009 ($ MILLIONS)
    • Education Gap
    • ABACAVIR, A PHARMACOGENOMICS SUCCESS STORY
  • Table 41 GLOBAL MARKET FOR ABACAVIR, BY REGION, THROUGH 2009 ($ MILLIONS)
  • Figure 9 GLOBAL MARKET FOR ABACAVIR, BY REGION, 2000-2009 ($ MILLIONS)
    • Abacavir, a Pharmacogenomics Success Story (continued)
• PHARMACOGENOMICS OF DRUG METABOLISM
  • DRUG METABOLISM BY CYTOCHROMES
    • P450 ISOZYMES AND PHARMACEUTICALS
  • Table 42 MAJOR CYTOCHROME P450 ISOZYMES
    • P450 Isozyme CYP3A
    • P450 Isozyme CYP2D6
    • P450 Isozyme CYP2C9
    • P450 Isozyme 2C19
    • P450 Isozyme 1A2
    • P450 DIAGNOSTIC TESTING
  • Table 43 GLOBAL MARKET FOR AMPLICHIP ARRAYS IN DIAGNOSTIC USE BY REGION, THROUGH 2009 ($ MILLIONS)
    • P450 TESTING FOR RESEARCH PURPOSES
  • Table 44 MAJOR SUPPLIERS OF CYTOCHROME P450 TESTING FOR RESEARCH PURPOSES
    • COMPETITION WITH PHENOTYPIC ASSAYS
• TECHNOLOGY
  • PATENTS AND COMMERCIALIZATION ISSUES
  • PATENT ANALYSIS
  • PATENT SHARE BY APPLICATION TYPE
  • Table 45 PHARAMCOGENOMICS PATENTS BY TECHNOLOGY, 2004
  • Table 46 PHARAMCOGENOMICS PATENTS BY DISEASE TARGET, 2004
    • PATENT SHARE BY REGION
  • Table 47 PHARMACOGENOMICS PATENTS BY REGION, 2004
  • Table 48 PHARMACOGENOMICS PATENTS BY ASSIGNEE, JANUARY 2004- JANUARY 2005
• INDUSTRY STRUCTURE
  • DRUG MARKET SEGMENTATION
  • MAJOR PHARMACOGENOMICS COMPANIES
  • Table 49 MAJOR PHARMACOGENOMICS COMPANIES ANNUAL SALES AND MARKET SHARES, 2004 ($ MILLIONS)
  • Table 49 (CONTINUED)
  • Figure 10 MAJOR PHARMACOGENOMICS COMPANIES ANNUAL SALES AND MARKET SHARES, 2004 (%)
    • COLLABORATIONS
  • Table 50 KEY COLLABORATIONS IN THE PHARMACOGENOMICS INDUSTRY
    • MYRIAD/ABBOTT
    • CURAGEN/PFIZER
    • DECODE/MERCK
    • DECODE/ROCHE
    • MILLENIUM/BAYER
    • ORCHID BIOSCIENCES/U.K. GOVERNMENT
    • LYNX/INSTITUTE FOR SYSTEMS BIOLOGY
    • NOVARTIS/CELERA
    • THIRD WAVE/RIKEN
    • IMPACT OF RELATED INDUSTRIES
      • NANOTECHNOLOGY
      • BIOINFORMATICS
    • ANALYSIS OF SUCCESSFUL COMPANIES
      • NOVARTIS - GLEEVEC/GLIVEC
        • Disease Target
        • Rapid Movement Through Trials
        • Orphan Drug Approval
        • Strong Brand Recognition
        • Continued Studies Identify New Target Populations
      • AFFYMETRIX, SANTA CLARA, CA
        • Marketing
        • Technical Support
        • Strategic Positioning
        • First Mover Status Maintained
        • Intellectual Property
• INTERNATIONAL ASPECTS
  • UNITED STATES
    • CENTRALIZED PHARMGKB DATABASE
    • FUNDING INITIATIVES
  • EUROPEAN UNION
    • NEW DRUG APPROVALS AND INNOVATION
    • R&D SPENDING IN THE EUROPEAN UNION
    • SOCIAL FACTORS
    • REGULATORY ENVIRONMENT
    • CHEAPER CLINICAL TRIALS
    • MIGRATION TO THE U.S.
  • JAPAN
    • NEW DRUG APPROVALS AND INNOVATION
    • REGULATORY ENVIRONMENT
    • LIMITED ACADEMIC-INDUSTRY COLLABORATION
    • VENTURE CAPITAL
  • OTHER GEOGRAPHIC AREAS
    • INTELLECTUAL PROPERTY
      • Intellectual Property (continued)
• ETHICAL CONSIDERATIONS
  • GENETIC EXCEPTIONALISM
  • PRIVACY
  • DEVELOPING NATIONS
  • DISCRIMINATION
  • GENES AND ENVIRONMENT
• IMPLICATIONS FOR THE FUTURE OF HEALTH CARE
  • EDUCATED DECISION-MAKING
  • RESPONSIBILITY FOR FAILURES
  • OVER-THE-COUNTER TESTS
  • DEFINITION OF ORPHAN DRUGS
    • DEFINITION OF ORPHAN DRUGS (CONTINUED)
• COMPANY PROFILES
  • ABBOTT LABORATORIES, ABBOTT PARK, IL
  • AMERSHAM (NOW GE HEALTHCARE), BUCKINGHAMSHIRE, UK
  • APPLERA CORPORATION, NORWALK, CT
  • ASTRAZENECA, ALDERLEY PARK, UK
  • CURAGEN CORPORATION, NEW HAVEN, CT
  • DAKOCYTOMATION, COPENHAGEN, DENMARK
  • DECODE GENETICS, REYKJAVIK, ICELAND
  • DXS, MANCHESTER, UK
  • ERAGEN, MASDISON, WI
  • FIVEPRIME THERAPEUTICS, SAN FRANCISCO, CA
  • GENAISSANCE PHARMACEUTICALS, NEW HAVEN, CT
  • GENENTECH, SOUTH SAN FRANCISCO, CA
  • GENTRIS, MORRISVILLE, NC
  • GLAXOSMITHKLINE, BRENTFORD, UK
  • HUMAN GENOME SCIENCES, ROCKVILLE, MD
  • ILLUMINA, SAN DIEGO, CA
  • INCYTE, PALO ALTO, CA
  • INTERLEUKIN GENETICS, WALTHAM, MA
  • LUMINEX CORP., AUSTIN, TX
  • MERCK, WHITEHOUSE STATION, NJ
  • MILLENIUM PHARMACEUTICALS, CAMBRIDGE, MA
  • MYRIAD GENETICS, INC., SALT LAKE CITY, UT
  • NANOGEN, SAN DIEGO, CA
  • NANOSPHERE, NORTHBROOK, IL
  • NITROMED, LEXINGTON, MA
  • ORCHID BIOSCIENCES, PRINCETON, NJ
  • PHARMASEQ, MONMOUTH JUNCTION, NJ
  • ROCHE (F. HOFFMANN-LA ROCHE LTD), BASEL, SWITZERLAND
  • SEQUENOM, SAN DIEGO, CA
  • THIRD WAVE, MADISON, WI
  • TM BIOSCIENCE CORP., TORONTO, ON, CANADA
  • WYETH, MADISON, NJ
• LIST OF TABLES
• Summary Table:
• Table 1 DRUG DEVELOPMENT AND FDA APPROVAL PROCESS
• Table 2 NME APPROVALS GRANTED BY FDA (UNITED STATES), 1995-2004
• Table 3 TOTAL SPENDING ON R&D BY PHRMA COMPANIES, 1999-2003 ($ BILLIONS)
• Table 4 R&D SPENDING ON CLINICAL DEVELOPMENT BY PHRMA COMPANIES, BY DRUG DEVELOPMENT PHASE, 2002 ($ BILLIONS)
• Table 5 DRUG INEFFICACY, BY THERAPY TYPE (PERCENTAGE OF PATIENTS FAILING TO RESPOND TO THERAPY)
• Table 6 ADVERSE DRUG REACTIONS IN THE UNITED STATES
• Table 7 PROMINENT DRUGS WITHDRAWALS
• Table 8 SNP CONSORTIUM MEMBERS
• Table 9 HAPMAP PARTICIPANTS AND FUNDING SOURCES
• Table 10 STRUCTURE OF THE INTERNATIONAL HAPMAP PROJECT
• Table 11 GLOBAL MARKET FOR SNP IDENTIFICATION TOOLS, THROUGH 2009 ($ MILLIONS)
• Table 12 EMERGING TECHNOLOGIES IN WHOLE GENOME MAPPING
• Table 13 MAJOR PRIVATE SNP DATABASES
• Table 14 GLOBAL MARKET FOR GENOTYPING TECHNOLOGIES BY PROTOCOL, THROUGH 2009 ($ MILLIONS)
• Table 15 COMPARATIVE ADVANATAGES OF ALLELIC DISCRIMINATION METHODS
• Table 16 GLOBAL MARKET FOR ALLELE DISCRIMINATION TECHNOLOGIES BY TYPE, THROUGH 2009 ($ MILLIONS)
• Table 17 TOTAL GLOBAL MICROARRAY MARKET AND THAT FOR GENOTYPING APPLICATIONS, THROUGH 2009 ($ MILLIONS)
• Table 18 COMPARATIVE ADVANATAGES OF DETECTION METHODS
• Table 19 STRENGTHS AND WEAKENESSES OF MASS SPECTROMETRY FOR GENOTYPING
• Table 20 EMERGING TECHNOLOGIES IN DNA MASS SPECTROMETRY
• Table 21 GLOBAL MARKET FOR GENOTYPING DETECTION TECHNOLOGIES BY TYPE, THROUGH 2009 ($ MILLIONS)
• Table 22 COMPARISON OF GENOTYPING PLATFORMS COST AND THROUGHPUT
• Table 23 GLOBAL MARKET FOR PHARMACOGENOMICS DIAGNOSTIC TOOLS BY TYPE, THROUGH 2009 ($ MILLIONS)
• Table 24 MAJOR SUPPLIERS OF PLANAR DNA MICROARRAYS
• Table 25 MAJOR SUPPLIERS OF BEAD MICROARRAYS
• Table 26 GLOBAL MARKET FOR MICROARRAYS IN PHARMACOGENOMICS BY TYPE, THROUGH 2009 (MILLIONS $)
• Table 27 MAJOR SUPPLIERS OF PCR-BASED ASSAYS
• Table 28 GLOBAL MARKET FOR PCR ASSAYS IN PHARMACOGENOMICS RESEARCH BY TYPE, THROUGH 2009 ($ MILLIONS)
• Table 29 COMPARISON OF FISH AND IHC TESTING FOR HER2
• Table 30 GLOBAL MARKET FOR IN SITU ASSAYS IN PHARMACOGENOMICS OF BREAST CANCER, THROUGH 2009 ($ MILLIONS)
• Table 31 PROJECTED BIDILR MARKET, THROUGH 2009 ($ MILLIONS)
• Table 32 MAJOR PRODUCERS OF STATINS
• Table 33 GLOBAL MARKET FOR HERCEPTIN, BY REGION, THROUGH 2009 ($ MILLIONS)
• Table 34 GLOBAL MARKET FOR GLEEVEC/GLIVEC, BY REGION, THROUGH 2009 ($ MILLIONS)
• Table 35 GLOBAL SALES OF IRESSA PRIOR TO FDA ANNOUNCEMENT, 2002-2004 ($ MILLIONS)
• Table 36 GENES OF INTEREST IN THE PHARMACOGENOMICS OF ASTHMA
• Table 37 MAJOR PLAYERS IN PHARMACOGENOMICS OF ASTHMA TREATMENT
• Table 38 GLOBAL MARKET FOR ASTHMA THERAPIES, BY TYPE, THROUGH 2009 ($ MILLIONS)
• Table 39 MAJOR SUPPLIERS OF HIV GENOTYPIC RESISTANCE TESTS
• Table 40 GLOBAL MARKET FOR HIV RESISTANCE TESTING BY REGION, THROUGH 2009 ($ MILLIONS)
• Table 41 GLOBAL MARKET FOR ABACAVIR, BY REGION, THROUGH 2009 ($ MILLIONS)
• Table 42 MAJOR CYTOCHROME P450 ISOZYMES
• Table 43 GLOBAL MARKET FOR AMPLICHIP ARRAYS IN DIAGNOSTIC USE BY REGION, THROUGH 2009 ($ MILLIONS)
• Table 44 MAJOR SUPPLIERS OF CYTOCHROME P450 TESTING FOR RESEARCH PURPOSES
• Table 45 PHARAMCOGENOMICS PATENTS BY TECHNOLOGY, 2004
• Table 46 PHARAMCOGENOMICS PATENTS BY DISEASE TARGET, 2004
• Table 47 PHARMACOGENOMICS PATENTS BY REGION, 2004
• Table 48 PHARMACOGENOMICS PATENTS BY ASSIGNEE, JANUARY 2004- JANUARY 2005
• Table 49 MAJOR PHARMACOGENOMICS COMPANIES ANNUAL SALES AND MARKET SHARES, 2004 ($ MILLIONS)
• Table 50 KEY COLLABORATIONS IN THE PHARMACOGENOMICS INDUSTRY
• LIST OF FIGURES
• Summary Figure:
• Figure 1 R&D SPENDING ON CLINICAL DEVELOPMENT BY PHRMA COMPANIES, BY DRUG DEVELOPMENT PHASE, 2002 ($ BILLIONS)
• Figure 2 GLOBAL MARKET FOR SNP IDENTIFICATION TOOLS, 2001-2009 ($ MILLIONS)
• Figure 3 GLOBAL MARKET FOR GENOTYPING TECHNOLOGIES BY PROTOCOL, 2001-2009 ($ MILLIONS)
• Figure 4 GLOBAL MARKET FOR ALLELE DISCRIMINATION TECHNOLOGIES BY TYPE, 2001-2009 ($ MILLIONS)
• Figure 5 GLOBAL MARKET FOR GENOTYPING DETECTION TECHNOLOGIES BY TYPE, 2001-2009 ($ MILLIONS)
• Figure 6 GLOBAL MARKET FOR PHARMACOGENOMICS DIAGNOSTIC TOOLS BY TYPE, 2001-2009 ($ MILLIONS)
• Figure 7 GLOBAL MARKET FOR MICROARRAYS IN PHARMACOGENOMICS BY TYPE, 2001-2009 (MILLIONS $)
• Figure 8 GLOBAL MARKET FOR PCR ASSAYS IN PHARMACOGENOMICS RESEARCH BY TYPE, 2001-2009 ($ MILLIONS)
• Figure 9 GLOBAL MARKET FOR ABACAVIR, BY REGION, 2000-2009 ($ MILLIONS)
• Figure 10 MAJOR PHARMACOGENOMICS COMPANIES ANNUAL SALES AND MARKET SHARES, 2004 (%)